How Far We Have Come Targeting BRAF-Mutant Non-Small Cell Lung Cancer (NSCLC)

BRAF belongs to the RAF family of serine/threonine kinases, which also includes ARAF and CRAF. RAF kinases are key players in the MAPK signaling pathway, which regulates cell proliferation, differentiation and survival (Figure 1). Almost two decades after the first report on cancer driver mutations in the BRAF kinase domain [1], nearly 300 distinct BRAF mutations have been identified in tumor samples and cancer cell lines from melanoma, colorectal cancer, papillary thyroid cancer and non-small cell lung cancer (NSCLC) [2].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research